Menu

Report Library

View More

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
7/17/25 GSK (GSK) Blenrep for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
7/16/25 Fortress Biotech (FBIO) CAEL-101 for Amyloid light-chain (AL) Amyloidosis Subscribers Only Subscribers Only Subscribers Only
7/16/25 Merck & Co (MRK) MK-8527 for HIV / AIDS Treatment Subscribers Only Subscribers Only Subscribers Only
7/15/25 Merck & Co (MRK) MK-8591B for HIV / AIDS Treatment Subscribers Only Subscribers Only Subscribers Only
7/15/25 Merck & Co (MRK) MK-8507 for HIV / AIDS Treatment Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/20/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/02/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update